A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
Protocol Chair: Jame Abraham, MD
Protocol Officer: Samuel Jacobs, MD
Primary Objective Phase Ib: To determine the safety and tolerability of T-DM1 and neratinib in patients with metastatic HER2-positive breast cancer.
Primary Objective: To determine the overall response rate (ORR) in patients with measurable metastatic breast cancer treated with T-DM1 and neratinib.
Patient Population: Metastatic HER2-Positive Breast Cancer
Target Accrual: 63 patients
Status: Closed to accrual
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402